Evidence map›Paper›PMID 41948465›Full record

ArticleMaterials today. Bio2026

Self-reinforcing nanoplatform uniting pemetrexed, magnetic hyperthermia and PD-L1 blockade reshapes the tumor microenvironment and elicits combined antitumor immunity in lung adenocarcinoma.

Zhengjun Guo, Xulin Xie, Wenxiu Li, Shouhui Yi, Emmanuel Koomson, Renardi Gunawan, Zhihang Zhou, Md Kowsar Alam, Li Zhou, Tongxu Si and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Zhengjun GuoDepartment of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xulin XieDepartment of Biomedical Sciences, and Tung Biomedical Sciences Centre, City University of Hong Kong, Hong Kong, China.
Wenxiu LiDepartment of Biomedical Sciences, and Tung Biomedical Sciences Centre, City University of Hong Kong, Hong Kong, China.
Shouhui YiDepartment of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Emmanuel KoomsonDepartment of Biomedical Sciences, and Tung Biomedical Sciences Centre, City University of Hong Kong, Hong Kong, China.
Renardi GunawanDepartment of Biomedical Sciences, and Tung Biomedical Sciences Centre, City University of Hong Kong, Hong Kong, China.
Zhihang ZhouDepartment of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Md Kowsar AlamDepartment of Biomedical Sciences, and Tung Biomedical Sciences Centre, City University of Hong Kong, Hong Kong, China.
Li ZhouDepartment of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Tongxu SiDepartment of Biomedical Sciences, and Tung Biomedical Sciences Centre, City University of Hong Kong, Hong Kong, China.
Zesheng WangDepartment of Biomedical Sciences, and Tung Biomedical Sciences Centre, City University of Hong Kong, Hong Kong, China.
Xiaoyu ZhouDepartment of Biomedical Sciences, and Tung Biomedical Sciences Centre, City University of Hong Kong, Hong Kong, China.
Yuan PengDepartment of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xiaoyue ZhangDepartment of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Zhenzhou YangDepartment of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Mengsu YangDepartment of Biomedical Sciences, and Tung Biomedical Sciences Centre, City University of Hong Kong, Hong Kong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer remains the leading cause of cancer-related mortality worldwide, and immune checkpoint blockade is often limited by an immunosuppressive tumor microenvironment (TME). To address these challenges, we developed a novel multifunctional nanoplatform, based on a mesoporous Fe

Indexed as

ImmunotherapyMesoporous silica nanoparticles (msNPs)Non-small cell lung cancer (NSCLC)T cell exhaustionThermotherapyTumor microenvironment (TME)

Identifiers

PMID41948465
PMCPMC13051971

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.